14 Publications in 2021
Cumulative IF: 273.7
Mean value IF: 19.55

1. Mitochondrial Telomerase Reverse Transcriptase Protects From Myocardial Ischemia/Reperfusion Injury by Improving Complex I Composition and Function
Ale-Agha N, Jakobs P, Goy C, Zurek M, Rosen J, Dyballa-Rukes N, Metzger S, Greulich J, von Ameln F, Eckermann O, Unfried K, Brack F, Grandoch M, Thielmann M, Kamler M, Gedik N, Kleinbongard P, Heinen A, Heusch G, Gödecke A, Altschmied J, Haendeler J
Circulation; 144:1876-1890    (Impact Factor = 39,918)

2. Guidelines for in vivo mouse models of myocardial infarction
Lindsey ML, Brunt KR, Kirk JA, Kleinbongard P, Calvert JW, Bras LED, DeLeon-Pennell KY, Del Re DP, Frangogiannis NG, Frantz S, Gumina RJ, Halade GV, Jones SP, Ritchie RH, Spinale FG, Thorp EB, Ripplinger CM, Kassiri Z
Am J Physiol-Heart Circul Physiol; 321:H1056-H1073    (Impact Factor = 5,125)

3. PCSK9 Activity Is Potentiated Through HDL Binding
Burnap SA, Sattler K, Pechlaner R, Duregotti E, Lu RF, Theofilatos K, Takov K, Heusch G, Tsimikas S, Fernandez-Hernando C, Berry SE, Hall WL, Notdurfter M, Rungger G, Paulweber B, Willeit J, Kiechl S, Levkau B, Mayr M
Circ Res; 129:1039-1053    (Impact Factor = 23,213)

4. Reinforcing rigor and reproducibility expectations for use of sex and gender in cardiovascular research
Lindsey ML, LeBlanc AJ, Ripplinger CM, Carter JR, Kirk JA, Keehan KH, Brunt KR, Kleinbongard P, Kassiri Z
Am J Physiol-Heart Circul Physiol; 321:H819-H824    (Impact Factor = 5,125)

5. IMproving Preclinical Assessment of Cardioprotective Therapies (IMPACT) criteria: guidelines of the EU-CARDIOPROTECTION COST Action
Lecour S, Andreadou I, Botker HE, Davidson SM, Heusch G, Ruiz-Meana M, Schulz R, Zuurbier CJ, Ferdinandy P, Hausenloy DJ
Basic Res Cardiol; 116:52    (Impact Factor = 12,416)

6. A pathophysiological compass to personalize antianginal drug treatment
Bertero E, Heusch G, Münzel T, Maack C
Nat Rev Cardiol; 18:838-852    (Impact Factor = 49,421)

7. Reperfused vs. nonreperfused myocardial infarction: when to use which model
Lindsey ML, Bras LED, DeLeon-Pennell KY, Frangogiannis NG, Halade GV, O'Meara CC, Spinale FG, Kassiri Z, Kirk JA, Kleinbongard P, Ripplinger CM, Brunt KR
Am J Physiol-Heart Circul Physiol; 321:H208-H213    (Impact Factor = 5,125)

8. The platelet paradox of injury versus protection in myocardial infarction-has it been overlooked?
Kleinbongard P, Andreadou I, Vilahur G
Basic Res Cardiol; 116:37    (Impact Factor = 12,416)

9. Noncanonical Thyroid Hormone Receptor alpha Action Mediates Arterial Vasodilation
Geist D, Hönes GS, Gassen J, Kerp H, Kleinbongard P, Heusch G, Führer D, Moeller LC
Endocrinology; 162:bqab099    (Impact Factor = 5,051)

10. Cardioprotection by post-conditioning with exogenous triiodothyronine in isolated perfused rat hearts and isolated adult rat cardiomyocytes
Lieder HR, Braczko F, Gedik N, Stroetges M, Heusch G, Kleinbongard P
Basic Res Cardiol; 116:27    (Impact Factor = 12,416)

11. We are the change we seek
Lindsey ML, Kassiri Z, Keehan KH, Brunt KR, Carter JR, Kirk JA, Kleinbongard P, LeBlanc AJ, Ripplinger CM
Am J Physiol-Heart Circul Physiol; 320:H1411-H1414    (Impact Factor = 5,125)

12. Myocardial stunning and hibernation revisited
Heusch G
Nat Rev Cardiol; 18:522-536    (Impact Factor = 49,421)

13. TheWest German Heart and Vascular Center at University Medicine Essen
Rassaf T, Heusch G
Eur Heart J; 42:963-964    (Impact Factor = 35,855)

14. Protection from cardiotoxicity of cancer chemotherapy: a novel target for remote ischaemic conditioning?
Heusch G, Rassaf T
Cardiovasc Res; 117:985-986    (Impact Factor = 13,081)